New trial tests which chemo combo best shrinks tough breast tumors
NCT ID NCT04138719
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells in the breast and lymph nodes at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin
What this could lead to
If it works, this could identify a more effective chemotherapy combination to shrink triple-negative breast tumors before surgery, potentially improving outcomes.
What could go wrong
This is a phase 2 trial, so results are preliminary. The study is still recruiting, and it's unclear if one combo will prove clearly better or safer than the other.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••